Literature DB >> 6608425

Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen.

M Shiraki, M Fujiwara.   

Abstract

Weekly injections of cyclophosphamide (Cy) at a dose of 20 mg/kg body weight prevented IgM to IgG class switch of serum anti-DNA antibodies and also immunoglobulin secreting cells in the spleen of MRL/Mp-lpr/lpr (MRL/1) mice. Culture experiments revealed that splenic B cells of Cy treated mice gave rise to more IgM and less IgG secreting cells than those of untreated mice in response to lipopolysaccharide. These results suggested that Cy suppressed enhanced differentiation of B cells into IgG secreting cells in MRL/1 mice, which would result in reduction of IgG anti-single stranded DNA antibodies and improvement of murine lupus like syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608425      PMCID: PMC1535928     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

2.  Anti-DNA antibodies and renal lesions of patients with systemic lupus erythematosus.

Authors:  D Koffler; V Agnello; R I Carr; H G Kunkel
Journal:  Transplant Proc       Date:  1969-12       Impact factor: 1.066

3.  LPS-induced autoantibody response. I. Ontogenic development of PFC response to bromelain-treated syngeneic erythrocytes.

Authors:  M Fujiwara; Y Akiyama
Journal:  Cell Immunol       Date:  1980-10       Impact factor: 4.868

4.  A plaque assay for all cells secreting Ig of a given type or class.

Authors:  E Gronowicz; A Coutinho; F Melchers
Journal:  Eur J Immunol       Date:  1976-08       Impact factor: 5.532

5.  19S and 17S antibody production in the cyclophosphamide- or methotrexate-treated rat.

Authors:  G W Santos; A H Owens
Journal:  Nature       Date:  1966-02-05       Impact factor: 49.962

6.  T cell regulation of polyclonal B cell responsiveness. I. Helper effects of T cells.

Authors:  M G Goodman; W O Weigle
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

7.  Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.

Authors:  J B Pennebaker; J N Gilliam; M Ziff
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

8.  Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.

Authors:  M Shiraki; M Fujiwara; S Tomura
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

9.  Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice.

Authors:  M W Steward; F C Hay
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

  9 in total
  3 in total

1.  Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice.

Authors:  H Kamada; Y Takaoka; K Kitagaki; H Nagai
Journal:  Inflamm Res       Date:  1995-11       Impact factor: 4.575

2.  Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine, an inhibitor of polyamine synthesis: II. Beneficial effects on the development of a lupus-like disease in MRL-lpr/lpr mice.

Authors:  N Claverie; J L Pasquali; P S Mamont; C Danzin; M Weil-Bousson; M Siat
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

3.  Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice.

Authors:  J Woo; T M Wright; B Lemster; D Borochovitz; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.